I received a ton of email about my bearish take on Cell Genesys(CEGE Quote) and its prostate cancer vaccine, GVAX Prostate, in last week's Mailbag. The column really set some of you off.
I'm accustomed to hearing from the bottom dwellers and the tin-foil-hat crowd, but oh boy, the curses and insults were flying! Too bad I can't share the best of these emails with you for laughs, but my editors are squeamish about such things.
Thankfully, some of you were a bit more genteel than the missile throwers. Which brings me to an email from Dilip S. He asks, "How can you say that GVAX is a dud? The phase II trials showed a median survival of over 35 months. If that's not an improvement over regular Taxotere, then what is? Am I missing something here?" ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet